Actuate Therapeutics (NASDAQ: ACTU) is developing elraglusib for metastatic pancreatic cancer. Its randomized Phase 2 study produced encouraging survival results when elraglusib was added to gemcitabine/nab-paclitaxel chemotherapy. Updated data presented at ASCO GI 2026 showed median overall survival of 10.1 months with elraglusib plus chemotherapy versus 7.2 months with chemotherapy alone, corresponding to a 38% reduction in the risk of death. The study met its primary overall-survival endpoint.

The longer-term survival data were particularly notable. At 12 months, 44.4% of patients receiving elraglusib plus chemotherapy were alive compared with 22.3% receiving chemotherapy alone. At 24 months, survival was 12.9% versus 2.6%, respectively. The study also reported numerical improvements in response rate, progression-free survival and disease-control rate. These Phase 2 findings do not establish that elraglusib will ultimately receive FDA approval, but they provide the clinical rationale for further development in a cancer with a very poor prognosis.

A striking valuation comparison: Actuate's recent market capitalization has been approximately $30 million, compared with more than $40 billion for Revolution Medicines (NASDAQ: RVMD) — a valuation difference of well over 1,000-fold. The comparison is particularly interesting because both companies are developing experimental treatments intended to improve outcomes in pancreatic cancer, although their drugs, clinical programs and development stages differ substantially.

Revolution's daraxonrasib has itself produced impressive clinical results, but its safety profile is an important part of the comparison. In a published Phase 1/2 study of previously treated pancreatic-cancer patients, 96% experienced treatment-related adverse events and 30% experienced Grade 3 or higher treatment-related adverse events. Frequently reported effects included rash, diarrhea, nausea, mouth inflammation (stomatitis/mucositis), vomiting and fatigue. In first-line monotherapy data reported by Revolution, 95% of patients experienced treatment-related adverse events and 38% had Grade 3 or higher events; common severe events included rash, diarrhea and stomatitis. These results should be considered alongside daraxonrasib's demonstrated antitumor activity and survival benefit, rather than interpreted to mean that the drug is unsafe or ineffective.